drugset / Trial / NCT04710134

Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma

NCT04710134

Phase 4 Completed 10 enrolled McMaster University Teva Canada · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

Dose escalation of reslizumab can ameliorate sputum eosinophilia in severe asthmatics who have persistent sputum eosinophilia despite treatment with reslizumab at the standard dose.

Timeline

Start
2021-02-10
Primary completion
2024-01-09
Completion
2024-01-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Reslizumab Monoclonal antibody 3 mg/kg Intravenous
Comparator Reslizumab Monoclonal antibody 4 mg/kg Intravenous
Comparator Reslizumab Monoclonal antibody 5 mg/kg Intravenous

Indications